In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
In a study, investigators observed that levels were higher in those with stage 3a than stage 3b chronic kidney disease.
The estimated potential staff time savings totaled 23 hours for an average facility with 70 patients, researchers found.
Rates of death and important non-fatal outcomes between ferumoxytol and iron sucrose or sodium ferric gluconate do not differ significantly.
For ICU patients, hemoglobin level thresholds vary with presence of comorbid heart disease.
Risk of anaphylaxis associated with IV iron highest for iron dextran, lowest for iron sucrose.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Patients prescribed the lipid-lowering agents were less likely to exhibit hyporesponsiveness to the medications.
Study finds no gender differences in parathyroid hormone, ferritin, Kt/V, or age.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
The association is independent of anemia, according to researchers.
Patients with vs. without protein-energy wasting syndrome had a significantly lower mean hemoglobin level.
Hepatitis C viral infection found to increase likelihood of requiring blood transfusions and hemoglobin levels dropping below 8.5 g/dL.
Iron deficiency may contribute to the relationship between proteinuria and excess FGF-23, researchers suggested.
The odds of major adverse cardiac events were 46% to 76% higher in anemic vs. non-anemic patients.
Unlike serum ferritin, transferrin saturation demonstrated an ability to predict the need for intravenous iron and ESA.
RED-HF study confirms the increased stroke risk observed in TREAT.
Successfully treating anemia in pre-dialysis CKD patients appears to prevent left ventricular remodeling.
Kidney disease patients with macroalbuminuria were 86% more likely to be anemic.
Trial stopped early due to a higher risk of serious cardiovascular events and infections with IV iron versus oral iron.
It was associated with a 15% reduced risk of early death among pre-dialysis, stage 5 chronic kidney patients treated with ESAs.
It reduces dose requirements and lowers the risk of death and hospitalization for cardiovascular complications compared with IV administration.
Researchers find link in the non-dialysis population.
Proteinuria, hyperphosphatemia, anemia linked more rapid annual decline in eGFR.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)